07

September

2022

The ICR scientists will present at the ESMO Annual Meeting this year. Here are some of the presentations.

Posted on September 7, 2022

Julia Bakker

At this year’s ESMO Annual Meeting, we take a look at some of the interesting research presented by Cancer Institute scientists and collaborators.

Next week, clinical oncologists and cancer researchers from around the world will meet in Paris to present, discuss and discuss the latest advances in cancer research.

The European Society for Medical Oncology (ESMO) Congress, one of Europe’s largest annual cancer conferences, will be held again from 9-13 September. The entire program will be available digitally for delegates unable to attend in person, while the networking opportunities and excitement of meeting colleagues face-to-face will ensure a festive atmosphere.

As always, ICR scientists will be present to present the latest scientific discoveries and the results of cutting-edge clinical trials.

Prior to and during ESMO 2022, we highlight several scientific presentations by researchers from ICR and its partner hospital, the Royal Marsden NHS Foundation Trust.

Access the entire program

Notable presentation

• Abstract 454O Presented by Christina Guo, Ph.D.
• Poster 827P presented by Professor Kevin Harrington on a Phase 1 study of modified viral RP2 alone and in combination with nivolumab in patients with solid tumors
• Abstract on Transcriptomic Signatures During Treatment of Advanced Prostate Cancer 1358O, ancillary study of the STAMPEDE trial led by Prof. Nick James, presented by Dr. Marina Parry, UCL Cancer Institute

• LBA62 in a phase III trial comparing the efficacy of abiraterone in combination with enzalutamide to abiraterone alone in patients with advanced hormone-sensitive prostate cancer. The study will be led by Prof. Nick James and Prof. Chris Parker, and the results will be presented by his Prof. Gert Attard at UCL Cancer Institute.

• A summary of 1359MO on studies comparing treatment response according to lymph node characteristics of metastasis as part of the STAMPEDE trial led by Professor Nick James. The study was published by his A Harran, Royal United Hospitals Bath.

• Susana Banerjee, Ph.D., 529MO Summary of Results from the Phase 2 MEDIOLA Trial Comparing Durvalumab With and Without Bevacizumab with Olaparib in Patients With BRCA Mutated Platinum-Sensitive Recurrent Ovarian Cancer

• poster 1697P on Treatment-Induced Cancer Evolution in BRCA Mutant and Non-BRCA Mutant Ovarian Cancer Models Led by Prof. Udai Banerji, Presented by Dr. Alvaro H. Ingles Russo Garces at The Royal Marsden

• Poster presented by Professor Johann de Bono on a study investigating whether tumor genetics are associated with long-term benefits of talazoparib in metastatic castration-resistant prostate cancer with altered DNA damage response 1368P
• LBA9 Summary of Initial Results from the RADICALS-HD Trial Examining Duration of Radiotherapy and Hormone Therapy After Prostate Cancer Surgery Presented by Professor Chris Parker

• Abstract 457MO on the Phase I trial M1774 in patients with solid tumors, led by Prof. Johann de Bono, was presented by Dr. Timothy Yap, The University of Texas MD Anderson Cancer Center, Houston, USA.

Get the latest on ESMO 2022

In addition, there are many research presentations in which ICR researchers have participated, as well as joint research presentations in which ICR researchers have participated. pay attention to our website, follow me on twitter To keep up the speed!

Provide comments